rs201060167
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong
The NM_002180.3(IGHMBP2):āc.1082T>Cā(p.Leu361Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000117 in 1,613,386 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: š 0.000092 ( 0 hom., cov: 32)
Exomes š: 0.00012 ( 0 hom. )
Consequence
IGHMBP2
NM_002180.3 missense
NM_002180.3 missense
Scores
8
10
1
Clinical Significance
Conservation
PhyloP100: 7.69
Genes affected
IGHMBP2 (HGNC:5542): (immunoglobulin mu DNA binding protein 2) This gene encodes a helicase superfamily member that binds a specific DNA sequence from the immunoglobulin mu chain switch region. Mutations in this gene lead to spinal muscle atrophy with respiratory distress type 1. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 9 uncertain in NM_002180.3
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.922
PP5
Variant 11-68929204-T-C is Pathogenic according to our data. Variant chr11-68929204-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 245627.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-68929204-T-C is described in Lovd as [Pathogenic]. Variant chr11-68929204-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
IGHMBP2 | NM_002180.3 | c.1082T>C | p.Leu361Pro | missense_variant | 8/15 | ENST00000255078.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
IGHMBP2 | ENST00000255078.8 | c.1082T>C | p.Leu361Pro | missense_variant | 8/15 | 1 | NM_002180.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152160Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
14
AN:
152160
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000558 AC: 14AN: 250754Hom.: 0 AF XY: 0.0000590 AC XY: 8AN XY: 135628
GnomAD3 exomes
AF:
AC:
14
AN:
250754
Hom.:
AF XY:
AC XY:
8
AN XY:
135628
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000119 AC: 174AN: 1461108Hom.: 0 Cov.: 32 AF XY: 0.000122 AC XY: 89AN XY: 726918
GnomAD4 exome
AF:
AC:
174
AN:
1461108
Hom.:
Cov.:
32
AF XY:
AC XY:
89
AN XY:
726918
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000919 AC: 14AN: 152278Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74458
GnomAD4 genome
AF:
AC:
14
AN:
152278
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74458
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ExAC
AF:
AC:
7
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 02, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 18, 2022 | Published functional studies demonstrate a damaging effect with severe loss of enzymatic activity compared to wild type (Eckart et al., 2012); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 18802676, 26922252, 14681881, 21353777, 17431882, 14506069, 16964485, 23566544, 33210134, 36077311, 27535533, 22157136, 25439726, 22965130, 24388491) - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 21, 2022 | - - |
Autosomal recessive distal spinal muscular atrophy 1;C4015349:Charcot-Marie-Tooth disease axonal type 2S Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 361 of the IGHMBP2 protein (p.Leu361Pro). This variant is present in population databases (rs201060167, gnomAD 0.01%). This missense change has been observed in individual(s) with distal spinal muscular atrophy type 1 and/or spinal muscular atrophy with respiratory distress type 1 (PMID: 14506069, 14681881, 18802676). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 245627). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on IGHMBP2 protein function. Experimental studies have shown that this missense change affects IGHMBP2 function (PMID: 22157136). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 30, 2020 | The p.L361P variant (also known as c.1082T>C), located in coding exon 8 of the IGHMBP2 gene, results from a T to C substitution at nucleotide position 1082. The leucine at codon 361 is replaced by proline, an amino acid with similar properties. This alteration has been reported in individuals presenting with early-onset disease, such as SMARD1 (Grohmann K et al. Ann. Neurol., 2003 Dec;54:719-24; Guenther UP et al. Hum. Mutat., 2007 Aug;28:808-15; Guenther UP et al. J. Mol. Med., 2009 Jan;87:31-41; Pitt M et al. Brain, 2003 Dec;126:2682-92). These individuals were reported to have a second IGHMBP2 alteration; however, the phase of the two alterations was only confirmed to be in trans in two individuals (Guenther UP et al. Hum. Mutat., 2007 Aug;28:808-15; Guenther UP et al. J. Mol. Med., 2009 Jan;87:31-41). Functional studies demonstrated that the p.L361P alteration leads to a severe loss of enzymatic activity of the IGHMBP2 protein (Eckart M et al. Pediatrics, 2012 Jan;129:e148-56). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Autosomal recessive distal spinal muscular atrophy 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Sep 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Charcot-Marie-Tooth disease, axonal, type 2S (MIM#616155) and neuronopathy, distal hereditary motor, type VI (MIM#604320). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from leucine to proline. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (15 heterozygotes, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated AAA domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported multiple times as pathogenic, and observed in compound heterozygous individuals with spinal muscular atrophy with respiratory distress (ClinVar, PMID: 23566544, PMID: 22157136). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Recombinant protein has been proven to result in significantly reduced enzyme activity through an ATPase assay (PMID: 22157136). (SP) 1201 - Heterozygous variant detected in trans with a second pathogenic heterozygous variant (p.(Cys496*)) in a recessive disease. (SP) 1206 - This variant has been shown to be paternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Charcot-Marie-Tooth disease axonal type 2S Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 10, 2022 | Variant summary: IGHMBP2 c.1082T>C (p.Leu361Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.6e-05 in 250754 control chromosomes. c.1082T>C has been reported in the literature in individuals affected with diaphragmatic palsy, Charcot-Marie-Tooth Disease or hereditary motor neuropathy. These data indicate that the variant is likely to be associated with disease. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Charcot-Marie-Tooth disease Uncertain:1
Uncertain significance, no assertion criteria provided | provider interpretation | Inherited Neuropathy Consortium | - | - - |
Distal spinal muscular atrophy Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at